Author: admin

Coupler.io Introduces AI Insights to Refine Marketing Reporting

The new product feature, AI Insights, lets professionals uncover and understand marketing data patterns 10x faster than manual analysis.

Coupler.io, an analytics platform, today launched AI Insights to address the reporting routine with a smarter approach to data interpretation. AI Insights by Coupler.io serves as an analytics advisor, shortening analysis time and giving marketers clarity on campaign performance. It solves a common challenge: too much data, too little time to act on it.

The feature automatically analyzes data in Coupler.io Dashboards and doesn’t require technical skills or manual input. It also follows ethical use of artificial intelligence, keeping data secure and private. By enabling this function, users get a recap of their real-time social media, advertising, and other digital marketing performance in under 30 seconds.

In essence, AI Insights by Coupler.io instantly delivers a summary of trends based on the displayed data in the dashboard. The following section identifies anomalies and patterns, as well as compares results to industry benchmarks. It enhances the analysis with concrete personalized recommendations to avoid drastic performance drops and achieve better results.

As Nika Tamaio Flores, a Product Lead at Coupler.io, highlights: “Treat AI Insights as a personal analyst, always ready to explain raw numbers and assist in optimizing marketing strategies.”

She adds, “It’s a microscope-type tool to unveil hidden data, allowing marketers not only to evaluate results but shape next steps. With less time spent digging through dashboards, there’s more room for human creativity and thinking.”

The AI Insights feature is mainly available in marketing dashboards, but the team has already implemented it in finance and sales reporting and will expand it to other areas.

At the same time, the product team is working on the Coupler.io MCP Server, a tool for analyzing large-scale datasets via natural language, as part of a broader push to expand AI across analytics. This direction supports the company’s mission to help businesses grow by making better use of their data.

About Coupler.io

Coupler.io is a no-code reporting automation and data analytics platform. It allows collecting, organizing, transforming, and visualizing business data to make informed decisions.

Media Contact
Company Name: Coupler.io
Contact Person: Dmytro Zaichenko
Email: Send Email
Country: United States
Website: https://www.coupler.io/

E-Motive Performance Ignites Mertztown’s Auto Scene with Custom Builds, Trusted Repairs, and a New Online Experience

E-Motive Performance Ignites Mertztown’s Auto Scene with Custom Builds, Trusted Repairs, and a New Online Experience

Mertztown, PA – June 23, 2025 – E-Motive Performance & Auto Repair, a shop located in the heart of Mertztown, PA, is proud to announce the launch of its all-new website. Since opening in 2024, the shop has quickly established itself as a go-to destination for both general auto repair and performance-driven upgrades, filling a long-standing gap in the Berks County automotive community.

Located at 244 Bowers Road, E-Motive Performance blends high-quality automotive care with cutting-edge customization. From routine maintenance and diagnostics to specialty Jeep modifications, suspension lift kits, and custom wheel and tire packages, the shop is helping drivers throughout the Lehigh Valley combine everyday reliability with bold, off-road-ready upgrades.

E-Motive Performance & Auto Repair

A New Standard for Auto Repair in Mertztown

Offering service for domestic, European, and Asian vehicles, including diesel repair on a case-by-case basis, E-Motive Performance delivers full-service capabilities that meet a wide variety of customer needs. Equipped with modern tools and a customer-focused approach, services include:

  • General auto repair and maintenance

  • Brake repair, engine diagnostics, and A/C service

  • Suspension upgrades and lift kits

  • Aftermarket wheels and tire packages

  • Jeep modifications and performance enhancements

From first inspection to final invoice, every step of the process is built for clarity, speed, and ease, making it simple for drivers to stay informed, in control, and back on the road without delays.

Performance Meets Personality: Jeep Mods, Lift Kits, and More

At the core of E-Motive’s offerings is a passion for helping customers bring personality to their vehicles. Jeep owners in particular have already taken note, as the shop has become known for its expertise in Jeep modifications, lift kits, and off-road suspension work.

In a region where traditional shops often limit their services to basic repair, E-Motive Performance stands out by offering a wider range of custom upgrades, without the long wait times or brand limitations found elsewhere. Whether it’s a daily driver needing maintenance or a full suspension overhaul for an off-road adventure vehicle, E-Motive provides the tools and skills to bring each project to life.

New Website Launching Soon: Designed with Drivers in Mind

As part of its growing digital presence, E-Motive Performance will soon unveil a completely redesigned website: www.e-motiveperformance.com. The upcoming launch of the all-new website is more than just a facelift—it’s a full digital upgrade designed to match the shop’s hands-on, high-performance experience. Built with real drivers in mind, it’s tailored to the needs of busy locals, passionate Jeep owners, and anyone looking for a shop that does things differently.

The new site will feature:

  • A modern design and easy-to-use layout

  • Mobile-friendly browsing for quick access on the go

  • A convenient service request form

  • Detailed breakdowns of core services, from diagnostics to lift kits

Whether planning a routine oil change, shopping around for “wheels and tires near me,” or mapping out the next big Jeep project, the new website will offer the tools, info, and confidence to move forward, any time, from anywhere.

About E-Motive Performance & Auto Repair

E-Motive Performance & Auto Repair is located at 244 Bowers Road, Mertztown, PA, serving drivers throughout Berks County and the surrounding Lehigh Valley area. The shop offers full-service auto repair along with advanced performance upgrades and custom solutions. With a focus on suspension lift kits, custom wheels and tires, Jeep modifications, and reliable diagnostics, E-Motive helps drivers enhance their vehicles with confidence, style, and speed.

For those seeking performance auto repair in PA or custom wheels and tires in Mertztown, E-Motive Performance offers a fresh take on automotive care, where precision meets personality.

Media Contact

E-Motive Performance & Auto Repair

244 Bowers Rd, Mertztown, PA 19539

(610) 360-5553

www.e-motiveperformance.com

Media Contact
Company Name: E-Motive Performance & Auto Repair
Contact Person: Representative
Email: Send Email
Address:244 Bowers Rd.
City: Mertztown
State: PA
Country: United States
Website: https://e-motiveperformance.com/

Severe Atopic Dermatitis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | GlaxoSmithKline, Arjil Pharma, Kymab, BiomX, LEO Pharma, SCM Lifescience, Sun Pharma, Brickell Biotech

The Key Severe Atopic Dermatitis Companies in the market include – Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others.

 

DelveInsight’s “Severe Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Severe Atopic Dermatitis, historical and forecasted epidemiology as well as the Severe Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Severe Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Atopic Dermatitis Market Forecast

 

Some of the key facts of the Severe Atopic Dermatitis Market Report:

  • The Severe Atopic Dermatitis market size was valued ~USD 10,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In April 2025, Kymera Therapeutics recently announced the start of patient dosing in its BroADen Phase Ib clinical trial, which is assessing KT-621—an oral, highly selective, and potent STAT6 degrader—in individuals with moderate to severe atopic dermatitis (AD). The company anticipates sharing results from the trial in the fourth quarter of 2025.

  • In April 2025, Corvus Pharmaceuticals revealed that new interim results from its randomized, double-blind, placebo-controlled Phase I trial of soquelitinib in patients with moderate to severe atopic dermatitis will be showcased through both an oral presentation and a poster at the Society for Investigative Dermatology meeting.

  • In February 2025, Apogee Therapeutics announced that the first patient has been dosed in Part B of its Phase II APEX clinical trial evaluating APG777 in individuals with moderate-to-severe atopic dermatitis (AD), and that enrollment for Part A of the trial has been completed.

  • In February 2025, The FDA has granted Fast Track designation to rezpegaldesleukin for treating patients aged 12 and older with moderate-to-severe atopic dermatitis that is either inadequately managed by topical prescription treatments or for whom such therapies are unsuitable.

  • In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe Severe Atopic Dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for Severe Atopic Dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.

  • In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat Severe Atopic Dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.

  • In October 2024, Eli Lilly’s EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe Severe Atopic Dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.

  • In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for Severe Atopic Dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe Severe Atopic Dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab’s response in adults with prurigo nodularis will also be shared.

  • In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for Severe Atopic Dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate Severe Atopic Dermatitis.

  • In the 7MM, the United States had the largest market size for Severe Atopic Dermatitis in 2023, with Japan following closely behind.

  • DUPIXENT, the first approved therapy for Severe Atopic Dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.

  • In 2023, there were approximately 53,348,000 diagnosed cases of Severe Atopic Dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.

  • In 2023, there were approximately 72,435,000 prevalent cases of Severe Atopic Dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.

  • In 2023, the total diagnosed cases of Severe Atopic Dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.

  • Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others

  • Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others

  • The Severe Atopic Dermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Atopic Dermatitis pipeline products will significantly revolutionize the Severe Atopic Dermatitis market dynamics.

 

Severe Atopic Dermatitis Overview

Severe Atopic Dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and dry skin. It is most frequently seen in children but can occur at any age. Severe Atopic Dermatitis is part of a group of allergic conditions, often referred to as the atopic triad, which also includes asthma and allergic rhinitis (hay fever).

 

Get a Free sample for the Severe Atopic Dermatitis Market Report:

https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market

 

Severe Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Severe Atopic Dermatitis Epidemiology Segmentation:

The Severe Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Severe Atopic Dermatitis

  • Prevalent Cases of Severe Atopic Dermatitis by severity

  • Gender-specific Prevalence of Severe Atopic Dermatitis

  • Diagnosed Cases of Episodic and Chronic Severe Atopic Dermatitis

 

Download the report to understand which factors are driving Severe Atopic Dermatitis epidemiology trends @ Severe Atopic Dermatitis Epidemiology Forecast

 

Severe Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Severe Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Severe Atopic Dermatitis Therapies and Key Companies

  • Bermekimab: Janssen Pharmaceutical

  • FB825: Oneness Biotech

  • Lebrikizumab: Eli Lily

  • Nemolizumab: Galderma

  • B244: AOBiome

  • Ruxolitinib: Incyte

  • Difelikefalin: Cara Therapeutics

  • Roflumilast: Arcutis Biotherapeutics

  • Rocatinlimab: Amgen/Kyowa Kirin

  • Tapinarof: Dermavant Sciences

  • KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics

  • Etrasimod: Pfizer/Arena pharmaceuticals

  • BMX-010: BioMimetix

 

Discover more about therapies set to grab major Severe Atopic Dermatitis market share @ Severe Atopic Dermatitis Treatment Market

 

Severe Atopic Dermatitis Market Drivers

  • Rising prevalence of Severe Atopic Dermatitis

  • Escalating expenditure on healthcare

  • Approvals of JAK inhibitors

  • Potential Emerging Therapies for Severe Atopic Dermatitis and pruritus

  • Increasing awareness about the condition

 

Severe Atopic Dermatitis Market Barriers

  • Over-the-counter medications

  • Outdated treatment recommendations

  • Poor prognosis and treatment adherence

  • Lack of timely diagnosis

  • Management of Severe Atopic Dermatitis in the primary care setting

 

Scope of the Severe Atopic Dermatitis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others

  • Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others

  • Severe Atopic Dermatitis Therapeutic Assessment: Severe Atopic Dermatitis current marketed and Severe Atopic Dermatitis emerging therapies

  • Severe Atopic Dermatitis Market Dynamics: Severe Atopic Dermatitis market drivers and Severe Atopic Dermatitis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Severe Atopic Dermatitis Unmet Needs, KOL’s views, Analyst’s views, Severe Atopic Dermatitis Market Access and Reimbursement

 

To know more about Severe Atopic Dermatitis companies working in the treatment market, visit @ Severe Atopic Dermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Severe Atopic Dermatitis Market Report Introduction

2. Executive Summary for Severe Atopic Dermatitis

3. SWOT analysis of Severe Atopic Dermatitis

4. Severe Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Severe Atopic Dermatitis Market Overview at a Glance

6. Severe Atopic Dermatitis Disease Background and Overview

7. Severe Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Atopic Dermatitis

9. Severe Atopic Dermatitis Current Treatment and Medical Practices

10. Severe Atopic Dermatitis Unmet Needs

11. Severe Atopic Dermatitis Emerging Therapies

12. Severe Atopic Dermatitis Market Outlook

13. Country-Wise Severe Atopic Dermatitis Market Analysis (2020–2034)

14. Severe Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Severe Atopic Dermatitis Market Drivers

16. Severe Atopic Dermatitis Market Barriers

17. Severe Atopic Dermatitis Appendix

18. Severe Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Severe Atopic Dermatitis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | GlaxoSmithKline, Arjil Pharma, Kymab, BiomX, LEO Pharma, SCM Lifescience, Sun Pharma, Brickell Biotech

Italian-Born Model and Tech Visionary Marzia Dorlando Launches Xchange: A Money-Free Bartering App for Real-World Trade

Los Angeles, CA – June 23, 2025 – International model, entrepreneur, DJ, and music producer Marzia Dorlando has officially launched Xchange, a peer-to-peer app that eliminates the need for money in everyday transactions. Designed for a new era of sustainability and community-driven connection, Xchange empowers users to trade goods and services directly—redefining the very idea of value in the modern world.

Born in Italy and now based in Los Angeles, Dorlando brings more than a decade of global experience at the intersection of fashion, innovation, and media to her role as Founder & CEO of Xchange. Her platform is quickly gaining attention as a bold solution for modern economic challenges—offering a refreshing, human-centered alternative to traditional market systems.

Xchange: A Digital Barter Ecosystem for a New Generation

Available now on the App Store, Xchange allows users to list what they have and what they need. From handyman services to vintage clothes, tutoring to photography, the app creates a live marketplace of barter opportunities—all tailored to a user’s local area. This revolutionary approach not only promotes reuse, recycling, and mutual aid, but also supports the growth of sustainability-first micro-economies.

Xchange is designed with simplicity and community in mind. Users can easily build profiles, message others, negotiate trades, and complete exchanges without a single dollar exchanged. The platform also encourages transparency, fairness, and trust by allowing ratings and reviews for each interaction.

Marzia Dorlando: From Media Influence to Real-World Impact

Known for her striking career in fashion and media, Dorlando has been featured in prestigious international magazines. But beyond her image, she’s long been an advocate for female entrepreneurship, social innovation, and sustainable living.

“It’s simple. You offer what you have, and ask for what you need,” says Marzia Dorlando. “Money doesn’t need to be part of the equation. Xchange brings us back to the basics of human connection, collaboration, and trust.

Her entrepreneurial spirit has evolved alongside her work in music production and DJing, helping her craft a unique brand at the crossroads of culture, creativity, and conscious tech. Xchange is the latest—and perhaps most impactful—embodiment of that vision.

The Future of Trade is Human-First

As global economies shift and people search for new ways to live more sustainably and affordably, Dorlando believes Xchange offers not just a platform, but a movement. “We are witnessing a cultural turning point,” she notes. “People are tired of systems that leave them behind. They want connection, creativity, and autonomy. Xchange delivers all three.”

Marzia Dorlando is inviting users across the U.S. and beyond to join the app, post their first trade, and become part of a growing network of changemakers redefining commerce—one swap at a time.

Download Xchange: https://apps.apple.com/us/app/xchange-service-goods/id6471430333

Follow Marzia Dorlando: @marziadorlando

Media Contact
Company Name: XCHANGE
Contact Person: Marzia Dorlando
Email: Send Email
Country: United States
Website: https://apps.apple.com/us/app/xchange-service-goods/id6471430333

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Italian-Born Model and Tech Visionary Marzia Dorlando Launches Xchange: A Money-Free Bartering App for Real-World Trade

New Brand Eco Love Launches to Offer Safer, Sustainable Alternatives to Plastic for U.S. Households

Eco Love, a new U.S.-based lifestyle brand, is officially launching with a line of safe, sustainable household products that offer a healthier alternative to plastic and low-grade metals.

Eco Love, a new U.S.-based lifestyle brand, is officially launching with a line of safe, sustainable household products that offer a healthier alternative to plastic and low-grade metals. The company is introducing families across the country to everyday essentials made from natural materials like glass, bamboo, and stainless steel — with the goal of helping households reduce toxic exposure and waste, one product at a time.

The launch includes a curated collection of bathroom, kitchen, and travel goods designed to replace common items that often contain harmful chemicals or unsustainable components.

“People are becoming more conscious of what they put in and around their bodies,” said a spokesperson for Eco Love. “We’re proud to offer a better option — one that’s safer, long-lasting, and kinder to the planet.”

A Cleaner, Safer Approach to Everyday Essentials

Scientific studies continue to show that everyday plastics and low-quality metals may leach toxic compounds — such as BPA, phthalates, lead, and cadmium — into the food we eat and the products we use on our bodies. These chemicals have been linked to hormone disruption, reproductive issues, and other long-term health concerns.

Eco Love addresses this problem by offering high-quality, non-toxic alternatives made with safe, natural materials.

Among the brand’s featured products:

  • Glass Food Storage Containers – A durable and chemical-free solution for meal prep and leftovers, available in multiple sizes.
  • Bamboo Toothbrushes – Biodegradable and naturally antibacterial, with soft charcoal bristles for effective oral care.
  • Stainless-Steel Water Bottles – Lightweight, BPA-free, and perfect for daily hydration without microplastics.
  • Wooden Soap Dishes and Brushes – Made from sustainable bamboo, designed to keep surfaces clean and reduce bacteria buildup.
  • Reusable Travel Sets – Portable bamboo utensil kits, mesh soap bags, and wooden combs for low-waste living on the go.

Each product is designed with functionality, longevity, and safety in mind — and all are shipped in plastic-free, recyclable packaging.

Everyday Swaps That Make a Difference

Eco Love focuses on offering practical swaps that feel natural and easy to adopt. From replacing plastic containers in the kitchen to upgrading grooming tools in the bathroom, the brand makes it simple to shift toward healthier materials without compromising on convenience or performance.

“Switching to glass or bamboo may seem small, but these changes add up,” the spokesperson said. “Our goal is to make it easy for people to choose better — for themselves and for the world around them.”

Eco Love’s approach helps consumers minimize exposure to harmful compounds while also cutting down on plastic waste that pollutes landfills and oceans.

Special Launch Offer

To celebrate its debut, Eco Love is offering 10% off first orders to customers who sign up for the brand’s VIP list. Subscribers will also get early access to new arrivals, promotions, and limited-edition releases.

A Brand with Purpose

Eco Love is more than a product line — it represents a growing shift toward intentional living and mindful consumption. Each item reflects a commitment to quality, safety, and sustainability — values that resonate with today’s health-conscious and environmentally aware consumers.

“We believe people deserve products they can trust,” said the spokesperson. “That means no hidden toxins, no throwaway designs — just thoughtful essentials made to last.”

Media Contact
Company Name: Eco Love
Contact Person: Public Relations
Email: Send Email
Address:224 W 35th St Ste 500 #2264
City: New York
State: NY 10001
Country: United States
Website: https://ecoloveonline.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Brand Eco Love Launches to Offer Safer, Sustainable Alternatives to Plastic for U.S. Households

New Jersey Gun Crime Lawyer Adam M. Lustberg Discusses Firearm Regulatory Violations

New Jersey gun crime lawyer Adam M. Lustberg (https://www.lustberglaw.com/blog/nj-2c_39-10-violation-of-the-regulatory-provisions-relating-to-firearms/) provides important insights into NJ 2C:39-10, a statute that governs violations of the regulatory provisions relating to firearms in the state. In a recent blog post published by Lustberg Law Offices, LLC, Lustberg details how this section of New Jersey’s criminal code targets actions that may not involve direct firearm misuse but still carry serious legal consequences. These include providing false information on firearm applications, failing to comply with licensing rules, and improperly transferring weapons.

The New Jersey gun crime lawyer explains that N.J.S.A. 2C:39-10 is often informally called the “falsification” statute. It emphasizes administrative compliance over misuse and serves as a framework to maintain integrity within the state’s gun control system. Lustberg outlines that offenses under this law can range from third- and fourth-degree crimes to disorderly persons offenses, all of which carry potential prison time, hefty fines, and lasting repercussions.

As a New Jersey gun crime lawyer, Adam M. Lustberg makes it clear that the law applies to both individuals and firearm dealers. It penalizes not just the false statements on applications but also illegal transfers to underage individuals, failures in mandatory reporting, and improper conduct by licensed dealers. “This law is not just about criminal misuse of firearms—it’s about maintaining transparency and accountability in every aspect of gun ownership and regulation,” Lustberg notes.

One key area discussed is subsection (c), which focuses on providing false details on applications for firearm permits or ID cards. This is considered a third-degree crime and is punishable by up to five years in prison and fines reaching $15,000. Another critical section includes subsections (e) and (f), which address the illegal transfer of firearms to individuals under 18 or handguns to those under 21. These violations can escalate to second-degree felonies with mandatory minimum prison sentences.

Lustberg also highlights subsection (a), which concerns firearm dealers and their responsibility to follow licensing and record-keeping rules. Violations here may result in fourth-degree criminal charges or disorderly persons offenses, depending on the specific breach. Selling a firearm without a proper license or failing to maintain transaction logs are examples cited that could attract penalties ranging from six months to 18 months in prison and fines up to $10,000.

In the article, Lustberg provides further context by noting that 2C:39-10 works in tandem with other firearm laws. For instance, providing false information may also lead to obstruction charges under N.J.S.A. 2C:29-1, and fraudulent firearm acquisition can escalate to unlawful possession under N.J.S.A. 2C:39-5.

The article also covers available defenses. Lustberg explains that these cases often revolve around regulatory breaches, meaning courts may weigh mitigating circumstances like lack of intent or honest mistakes. For instance, omitting a past conviction unintentionally or misunderstanding a question on an application form could serve as a basis to challenge the charge. “Demonstrating a lack of intent can lead to reduced charges or dismissal,” he explains.

Other legal defenses discussed include challenging the sufficiency of evidence, invoking statutory exceptions such as supervised youth hunting or target shooting, and raising procedural errors committed by law enforcement during investigation. The possibility of Pre-Trial Intervention (PTI) is also raised, particularly for first-time offenders, as a way to avoid a criminal record if the program is successfully completed.

Lustberg underscores the seriousness of facing a charge under 2C:39-10, as even procedural missteps can lead to a permanent criminal record and loss of firearm rights. These penalties can have a profound impact on a person’s ability to find employment or pass background checks. Still, he emphasizes that understanding the statute and responding quickly can help defendants find viable legal paths forward.

NJ 2C:39-10 represents a detailed and far-reaching part of New Jersey’s firearm laws, with penalties targeting those who fail to comply with both minor and significant regulatory mandates. Adam M. Lustberg makes it clear that anyone facing such charges must approach the situation with care and seek guidance grounded in state firearm law.

Violations of NJ 2C:39-10 are more than technical errors, they are treated as serious breaches of public safety. Anyone charged under this statute should understand their legal standing and take immediate steps to protect their rights and future opportunities.

Lustberg Law Offices, LLC provides legal support to individuals dealing with NJ 2C:39-10 charges. The team reviews the facts, identifies defenses, and offers representation to minimize the consequences. Legal options may include negotiations, PTI programs, or building a defense around lack of intent or improper procedure by authorities.

About Lustberg Law Offices, LLC:

Lustberg Law Offices, LLC, led by Adam M. Lustberg, represents clients across New Jersey in criminal matters, including those involving firearm regulations. The firm handles a wide range of charges with a focus on providing accurate information and legal representation to those navigating the criminal justice system.

Embeds:

Youtube Video: https://www.youtube.com/watch?v=8vEYgAALjVA

GMB: https://www.google.com/maps?cid=17248268094099978177

Email and website

Email: alustberg@lustberglaw.com

Website: https://www.lustberglaw.com/

Media Contact
Company Name: Lustberg Law Offices, LLC
Contact Person: Adam M. Lustberg
Email: Send Email
Phone: (201) 880-5311
Address:One University Plaza Dr Suite 212
City: Hackensack
State: New Jersey 07601
Country: United States
Website: https://www.lustberglaw.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Jersey Gun Crime Lawyer Adam M. Lustberg Discusses Firearm Regulatory Violations

The Boulder Group Arranges Sale of Single Tenant Family Dollar in North Carolina

The Boulder Group has completed the sale of a single tenant Family Dollar located at 1257 Goldrock Rd in Rocky Mount, NC for $1,100,000. The Boulder Group’s Brandon Wright and Zach Wright exclusively represented the seller in the transaction. The seller was a private investor based in Virginia and the purchaser was a North Carolina-based 1031 exchange investor. This was an all-cash transaction that closed quickly.

The Family Dollar property is located along Goldrock Road and is positioned just north of Golden East Crossing, an 825,000 square foot regional mall. Rocky Mount is located approximately 55 miles east of Raleigh and there are over 45K people living within a five-mile radius of the property.

Family Dollar has a long operating history at this location and recently extended their lease for an additional five years demonstrating commitment to the location. Family Dollar is one of the largest dollar store retailers in the nation with approximately 8,000 stores.

“STNL properties with low price points and proven successful operating histories continue to garner strong investor demand,” stated Zach Wright, Vice President.

“We were able to generate multiple offers for this Family Dollar property despite some recent negative publicity on the company regarding store closures and Dollar Tree’s sale of Family Dollar. Investors remain interested in Family Dollar properties with low price points in good locations with proven operating histories,” said Brandon Wright, Associate.

About The Boulder Group

The Boulder Group is a boutique investment real estate service firm specializing in single tenant net lease properties. The firm provides a full range of brokerage, advisory, and financing services nationwide to a substantial and diversified client base, which includes high-net-worth individuals, developers, REITs, partnerships and institutional investment funds. Founded in 1997, the firm has arranged the acquisition and disposition of over $9 billion of single tenant net lease real estate transactions. From 2013-2024, the firm was ranked in the top 10 companies in the nation for single tenant retail transactions by both Real Capital Analytics and CoStar. The Boulder Group is headquartered in suburban Chicago and has an office in Denver.

For additional information, please visit www.BoulderGroup.com

Media Contact
Company Name: The Boulder Group
Contact Person: Zach Wright
Email: Send Email
Phone: 720-604-2220
Address:1805 S Bellaire Street, Suite 355
City: Denver
State: Colorado
Country: United States
Website: https://www.bouldergroup.com/NNN-Properties-For-Sale.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Boulder Group Arranges Sale of Single Tenant Family Dollar in North Carolina

Greenfield & Associates, LLP Sweeps Platinum Awards Across Five Categories

Huntington Beach, California – Greenfield & Associates, LLP is proud to announce its outstanding recognition as a Platinum Award Winner in five major categories, solidifying its place as a trusted leader in financial and administrative services.

In a competitive field of nominees, Greenfield & Associates, LLP was awarded Platinum in the following categories:

• Accountants

• Accounting Firms

• Administrative Services

• Bookkeeping

• Income Tax Preparation

“These awards reflect the trust our clients place in us, especially in the areas that impact their financial health most directly — tax planning and accurate, timely bookkeeping,” said Susan Luong, Managing Partner at Greenfield & Associates, LLP. “Whether we’re helping a small business stay compliant and organized or guiding families through complex tax strategies, our team brings precision, transparency, and peace of mind.”

Each Platinum award reflects the highest level of distinction in its category, based on public votes and professional accolades. The firm’s ability to deliver exceptional results across multiple service lines demonstrates its versatility and dedication to meeting the evolving needs of individuals and businesses alike.

Greenfield & Associates, LLP has built its reputation by delivering hands-on support, year-round tax planning, and meticulous financial recordkeeping tailored to each client’s goals. The firm’s recognition in these categories underscores its commitment to delivering personalized, proactive solutions that go far beyond basic compliance.

This milestone would not be possible without the continued support of the firm’s clients and the dedication of its talented professionals. Greenfield & Associates, LLP remains committed to empowering clients with smart tax strategies and clear, reliable bookkeeping — the foundation of any strong financial future.

About Greenfield & Associates, LLP

Greenfield & Associates, LLP is a full-service accounting and consulting firm known for delivering accurate, strategic, and client-centered solutions. With a strong reputation built on years of expertise and personal attention, the firm offers services in accounting, tax preparation, tax planning, bookkeeping, administrative support, and more.

For media inquiries or more information, please contact:

Sky Pham, Managing Partner

Phone: 949-973-1040

Email: partners@greenfieldllp.us

Website: https://www.greenfieldllp.us

Media Contact
Company Name: GREENFIELD & ASSOCIATES, LLP
Contact Person: SKY PHAM
Email: Send Email
Country: United States
Website: https://www.greenfieldllp.us

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Greenfield & Associates, LLP Sweeps Platinum Awards Across Five Categories

12-Year-Old Competes at the 2025 IBJJF American Nationals in Las Vegas

Mason Des Jardins, a 12 year old Jiu Jitsu athlete from Annapolis, MD will compete at the International Brazilian Jiu Jitsu Federation (IBJJF) American Nationals.

ANNAPOLIS, MD – June 23, 2025 – Mason Des Jardins, a rising star from Team Randori Martial Arts, will compete in the prestigious IBJJF American Nationals in Las Vegas, Nevada, from January 26–28, 2025. This event is one of the largest and most respected Brazilian Jiu-Jitsu tournaments in the world, drawing top athletes from around the globe. As Mason pursues his dream of becoming a Jiu-Jitsu World Champion, this tournament represents a crucial milestone in his journey.

The International Brazilian Jiu-Jitsu Federation (IBJJF) is renowned for its global presence in the sport of Brazilian Jiu-Jitsu. With a mission to promote, organize, and regulate BJJ competitions worldwide, the IBJJF hosts top-tier events such as the World Jiu-Jitsu Championship, Pan Jiu-Jitsu Championship, European Open, and the American Nationals. Known for its adherence to standardized rules and ranking systems, the IBJJF provides a platform for athletes of all ages and skill levels to showcase their talent on the global stage.

The 2025 IBJJF American National Jiu-Jitsu Championship will take place at the Las Vegas Convention Center, promising an electric three-day event from June 26–28, 2025. Athletes in both GI and No-GI formats will compete in juvenile, adult, and master divisions, with the event expected to be a thrilling display of grappling excellence.

For Mason, a dedicated competitor with just over four years of BJJ experience, the American Nationals will be his next major step toward achieving his ultimate goal of becoming a Kids World Champion. Throughout his journey, Mason has consistently impressed, taking top honors at several IBJJF tournaments and demonstrating his growing skills and determination.

After the American Nationals, Mason will set his sights on the IBJJF Kids Pan American Championship, scheduled for July 25–27, 2025, in Kissimmee, FL, followed by the IBJJF Kids CON in Las Vegas on August 28–29, 2025.

“We are incredibly proud to have such a talented and driven athlete at Team Randori,” said Al Hogan, Owner and Instructor of Team Randori Martial Arts. “Mason’s discipline, focus, and intensity inspire everyone in the gym to push themselves harder and realize that they, too, can achieve greatness.”

Mason’s head coach, Professor Guilherme Neves, a 3rd Degree Black Belt and Head Instructor at Team Randori, has played a pivotal role in shaping Mason’s competitive edge. Neves is known for coaching several athletes to world championships, including multiple gold medalists at the 2024 Kids Pan American Championships.

For more information, visit www.teamrandori.com or contact us at teamrandori@gmail.com for training inquiries.

About Team Randori Martial Arts

Founded in 2013, Team Randori Martial Arts is a leading provider of Brazilian Jiu-Jitsu and Self-Defense instruction in the greater Baltimore, MD area. With a focus on technical excellence and personal growth, Team Randori is committed to developing athletes of all ages and skill levels.

Contact:

Team Randori Martial Arts

Email: teamrandori@gmail.com

Website: www.teamrandori.com

Media Contact
Company Name: Team Randori Martial Arts. Annapolis, MD
Contact Person: Alfred Hogan
Email: Send Email
Country: United States
Website: http://www.teamrandori.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 12-Year-Old Competes at the 2025 IBJJF American Nationals in Las Vegas

Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Precigen, Inovio Pharma

The Key Recurrent Respiratory Papillomatosis Companies in the market include – Precigen, Inc., Inovio Pharmaceuticals, and others.

 

DelveInsight’s “Recurrent Respiratory Papillomatosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Recurrent Respiratory Papillomatosis, historical and forecasted epidemiology as well as the Recurrent Respiratory Papillomatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Recurrent Respiratory Papillomatosis, offering comprehensive insights into the Recurrent Respiratory Papillomatosis revenue trends, prevalence, and treatment landscape. The report delves into key Recurrent Respiratory Papillomatosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Recurrent Respiratory Papillomatosis therapies. Additionally, we cover the landscape of Recurrent Respiratory Papillomatosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Recurrent Respiratory Papillomatosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Recurrent Respiratory Papillomatosis space.

 

To Know in detail about the Recurrent Respiratory Papillomatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Recurrent Respiratory Papillomatosis Market Forecast

 

Some of the key facts of the Recurrent Respiratory Papillomatosis Market Report:

  • The Recurrent Respiratory Papillomatosis market size was valued ~USD 10.26 million in 2023 and is anticipated to grow with a significant CAGR of 39.9% during the study period (2020-2034)

  • In February 2025, INOVIO (NASDAQ: INO), a biotechnology company focused on developing DNA medicines for HPV-related conditions, cancer, and infectious diseases, announced that peer-reviewed results from its Phase 1/2 trial of INO-3107 for recurrent respiratory papillomatosis (RRP) have been published in Nature Communications. The study, titled DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107, revealed that INO-3107 stimulated new T cell populations in the blood that migrated to the airway and papilloma tissues, correlating with fewer surgeries post-treatment. Of the 32 patients enrolled, 26 (81%) needed fewer surgical interventions after treatment compared to the year before. The therapy was also well tolerated. INOVIO intends to submit a Biologics License Application (BLA) for INO-3107 by mid-2025 and will seek rolling submission and priority review through the FDA’s accelerated approval pathway. If approved, INO-3107 would become the first DNA-based medicine approved for any condition in the U.S.

  • In December 2024, Precigen, Inc. announced that it has completed the submission of its biologics license application (BLA) to the FDA for PRGN-2012 (zopapogene imadenovec†) as a treatment for adult recurrent respiratory papillomatosis (RRP).

  • In August 2024, Precigen announced a strategic shift to concentrate on the potential commercialization of PRGN-2012. As part of this realignment, the company will reduce its workforce by 20% and halt all preclinical programs. This decision highlights Precigen’s dedication to advancing PRGN-2012 and reallocating resources to enhance its commercial potential.

  • The EU4 and the UK represented about 16% of the 7MM market size, with the RRP market valued at approximately USD 1.66 million in 2023.

  • In 2023, Germany had the largest market size for RRP among the EU countries, reaching nearly USD 0.45 million, whereas Spain had the smallest market size, approximately USD 0.25 million.

  • The overall market size of RRP is expected to increase during the forecast period, driven by the anticipated introduction of emerging therapies such as INO-3107, PRGN-2012, and others.

  • Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others

  • Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others

  • The Recurrent Respiratory Papillomatosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Recurrent Respiratory Papillomatosis pipeline products will significantly revolutionize the Recurrent Respiratory Papillomatosis market dynamics.

  • The total number of diagnosed prevalent cases of RRP in the US was approximately 16,980 in 2023 and is expected to rise during the forecast period.

  • According to DelveInsight’s estimates, the US has the highest number of diagnosed prevalent cases of RRP among the 7MM, followed by the EU4 and the UK, with Japan contributing to 24% and 10% of all RRP cases, respectively.

  • In 2023, Japan reported the highest number of RRP cases in adults aged 18 and older (~2,400), followed by adolescents aged 9-17 years (~50). The fewest cases were observed in children aged 0-8 years, with a total of approximately 25.

  • In 2023, the EU4 and the UK reported a total of approximately 6,240 diagnosed prevalent cases of RRP, with around 5,740 cases linked to HPV 6 and/or HPV 11, and about 500 cases associated with other high-risk subtypes such as HPV-16, 18, 31, 33, and 39. The large number of cases related to HPV 6 and 11 highlights the dominant role these strains play in RRP, as they are the primary causative agents.

  • In 2023, Germany reported the highest number of diagnosed prevalent RRP cases among the EU4 and the UK, with nearly 1,684 cases. France followed with around 1,370 cases, Italy had approximately 1,220, the UK reported about 1,022, and Spain had the lowest with roughly 944 cases. This distribution underscores the differing disease burden across European countries.

 

Recurrent Respiratory Papillomatosis Overview

Recurrent Respiratory Papillomatosis (RRP) is a rare condition characterized by the growth of benign tumors, called papillomas, in the airways, primarily affecting the larynx, trachea, and bronchi. These growths are caused by infection with the human papillomavirus (HPV), particularly types 6 and 11. RRP can lead to airway obstruction, hoarseness, breathing difficulties, and recurrent infections. The condition is chronic, often requiring repeated surgical interventions to remove the papillomas. It can occur in both children (juvenile-onset RRP) and adults (adult-onset RRP), with varying severity and progression.

 

Get a Free sample for the Recurrent Respiratory Papillomatosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/recurrent-respiratory-papillomatosis-market

 

Recurrent Respiratory Papillomatosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Recurrent Respiratory Papillomatosis Epidemiology Segmentation:

The Recurrent Respiratory Papillomatosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Recurrent Respiratory Papillomatosis

  • Prevalent Cases of Recurrent Respiratory Papillomatosis by severity

  • Gender-specific Prevalence of Recurrent Respiratory Papillomatosis

  • Diagnosed Cases of Episodic and Chronic Recurrent Respiratory Papillomatosis

 

Download the report to understand which factors are driving Recurrent Respiratory Papillomatosis epidemiology trends @ Recurrent Respiratory Papillomatosis Epidemiology Forecast

 

Recurrent Respiratory Papillomatosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Respiratory Papillomatosis market or expected to get launched during the study period. The analysis covers Recurrent Respiratory Papillomatosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Recurrent Respiratory Papillomatosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Recurrent Respiratory Papillomatosis Therapies and Key Companies

  • PRGN-2012: Precigen, Inc.

  • INO-3107: Inovio Pharmaceuticals

 

Discover more about therapies set to grab major Recurrent Respiratory Papillomatosis market share @ Recurrent Respiratory Papillomatosis Treatment Landscape

 

Recurrent Respiratory Papillomatosis Market Drivers

  • Increasing Incidence of HPV Infections

  • Advancements in Surgical and Therapeutic Options

  • Rising Awareness and Early Diagnosis

  • Improved Treatment Modalities

  • Research and Development Investments

 

Recurrent Respiratory Papillomatosis Market Barriers

  • Limited Awareness and Diagnosis

  • Lack of Cure

  • High Treatment Costs

  • Fragmented Treatment Landscape

  • Limited Availability of Effective Therapies

  • Challenges in HPV Vaccination Implementation

 

Scope of the Recurrent Respiratory Papillomatosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Recurrent Respiratory Papillomatosis Companies: Precigen, Inc., Inovio Pharmaceuticals, and others

  • Key Recurrent Respiratory Papillomatosis Therapies: PRGN-2012, INO-3107, and others

  • Recurrent Respiratory Papillomatosis Therapeutic Assessment: Recurrent Respiratory Papillomatosis current marketed and Recurrent Respiratory Papillomatosis emerging therapies

  • Recurrent Respiratory Papillomatosis Market Dynamics: Recurrent Respiratory Papillomatosis market drivers and Recurrent Respiratory Papillomatosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Recurrent Respiratory Papillomatosis Unmet Needs, KOL’s views, Analyst’s views, Recurrent Respiratory Papillomatosis Market Access and Reimbursement

 

To know more about Recurrent Respiratory Papillomatosis companies working in the treatment market, visit @ Recurrent Respiratory Papillomatosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Recurrent Respiratory Papillomatosis Market Report Introduction

2. Executive Summary for Recurrent Respiratory Papillomatosis

3. SWOT analysis of Recurrent Respiratory Papillomatosis

4. Recurrent Respiratory Papillomatosis Patient Share (%) Overview at a Glance

5. Recurrent Respiratory Papillomatosis Market Overview at a Glance

6. Recurrent Respiratory Papillomatosis Disease Background and Overview

7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Recurrent Respiratory Papillomatosis

9. Recurrent Respiratory Papillomatosis Current Treatment and Medical Practices

10. Recurrent Respiratory Papillomatosis Unmet Needs

11. Recurrent Respiratory Papillomatosis Emerging Therapies

12. Recurrent Respiratory Papillomatosis Market Outlook

13. Country-Wise Recurrent Respiratory Papillomatosis Market Analysis (2020–2034)

14. Recurrent Respiratory Papillomatosis Market Access and Reimbursement of Therapies

15. Recurrent Respiratory Papillomatosis Market Drivers

16. Recurrent Respiratory Papillomatosis Market Barriers

17. Recurrent Respiratory Papillomatosis Appendix

18. Recurrent Respiratory Papillomatosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Respiratory Papillomatosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Precigen, Inovio Pharma